Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
← catalyst calendarSponsored by Tango Therapeutics, Inc. (industry) · TNGX — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
225estimated
Sites
26
Countries
France, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-05-26 | actual | When the study began enrolling |
| Primary completion | May 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2023-02-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Locally Advanced Solid Tumor
Interventions
- Drug: TNG462
- Drug: Pembrolizumab — also filed as Keytruda
Primary outcomes
what the primary-completion date above is the date OFPhase 1 Maximum Tolerated Dose
measured 28 days and 21 days
Phase 1 Dosing Schedule
measured 28 days
Phase 2 Anti-neoplastic Activity
measured 16 weeks and 18 weeks
Permalink · TNGX's whole pipeline · Catalyst calendar · Every registered study · What changed